Clinical trials for advancing innovative interventions for neurodegenerative diseases
EU-wide funded clinical studies for the research and validation of innovative, multidisciplinary therapeutic approaches in neurodegenerative diseases. Two-stage procedure with submission deadlines on 13.04.2027 (Stage 1) and 22.09.2027 (Stage 2).
Discover your potential with AI support
- Find out if this grant matches your project
- Develop your application together with AI
- Get matched with many more suitable grants
Grant criteria
Funding objective
Funding of rigorous, early-phase clinical studies to evaluate the safety and efficacy of novel interventions in neurodegenerative diseases, combined with multidisciplinary approaches such as lifestyle changes or rehabilitation, to improve quality of life and reduce societal burden.
Eligible expenses
- Personnel expenses
- Material costs
- Travel expenses
- Subcontractor services
Non-eligible expenses
- Acquisition of real estate
- Retroactive costs
- Debt settlement
Eligible to apply
- Companies
- Educational Institutions
- Non-profit Organizations
- Public Institutions
Funding requirements
- Consortium of at least three independent legal entities from three different EU Member States or associated countries
- Experience in EU-funded research projects of comparable size
- Compliance with Horizon Europe participation conditions (e.g., no exclusion due to sanctions)
- Proof of financial and operational capacity through PIC validation
Documents required for application
- Application form (Part A)
- Project description (Part B)
- Disclosure plan for exploitation and communication
- Curricula vitae of key personnel
- Financial plan
Evaluation criteria
- Excellence of the project
- Impact and dissemination
- Quality and efficiency of implementation
Description
The EU initiative “Clinical trials for advancing innovative interventions for neurodegenerative diseases” supports cross-border clinical studies with a multidisciplinary approach to explore safe and effective therapeutic options. Companies, research institutions, non-profit and public organizations from at least three different EU Member States or associated countries can receive grants averaging €10 million per project. Funding covers personnel and material costs, travel expenses, as well as subcontractor services over a period of up to 48 months. A consortium with experience in EU-funded research projects and proven financial and operational capacity is required. The Horizon Europe participation conditions and the anti-sanctions clause must be met. The funding covers 100% of eligible costs, provided that real estate purchases, retroactive expenses, and debt settlements are excluded.
The focus is on early-phase Phase I/II studies combining pharmacological agents with complementary lifestyle, rehabilitation, or digital monitoring approaches. The goal is to improve quality of life and reduce societal burden in diseases such as Alzheimer’s or Parkinson’s. Involvement of patients, caregivers, clinicians, regulatory authorities, and experts from the social sciences is intended to ensure patient orientation and dissemination of results. Submission follows a two-stage procedure: Stage 1 by 13 April 2027, Stage 2 by 22 September 2027. Required attachments include, among others, the application form Part A, the project description Part B, a disclosure plan, CVs of key personnel, and a financing plan. Awarded projects are encouraged to publish their findings in EU data infrastructures and participate in future partnership networks.
Ready to secure your funding?
Register now and let our AI guide you through the application process – from eligibility check to finished application.